Scholars Central

Research articlePublished 13 Nov 2015

Daclatasvir/Asunaprevir Therapy Provides High Tolerability and Effectiveness for HCV-Positive Kidney Transplant Recipients

Authors: Tomomi Kogiso, Etsuko Hashimoto, Kuniko Yamamoto, Yuichi Ikarashi, Kazuhisa Kodama, Makiko Taniai, Nobuyuki Torii, Kazunari Tanabe, Hideki Ishida, Shohei Fuchinoue, Katsutos

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background/Aims: Hepatitis C virus (HCV) infection is not rare in kidney transplant (KT) recipients. Interferon (IFN)-based therapies are generally contraindicated because IFN can induce severe rejection of the allograft. Here, we report five cases those who underwent therapy with direct-acting antiviral drugs (DAAs) after KT and evaluated their clinical outcomes. Patients/Methods: The five patients [the median age; 55 (49- 71) years, 3 males], were treated with NS5A and NS3 proteasetargeted DAA (daclatasvir, DCV and asunaprevir, ASV) therapy for 24 weeks after KT. The immunosuppressants prescribed were corticosteroids/mammalian target of rapamycin, tacrolimus, and mycophenolate mofetil or azathioprine. Results: In all cases, the acquired HCV was serological type 1 with the L31 or Y93 wild-type strain and the median HCV RNA level was 6.5 (5.7-6.7) log IU/mL. The median estimated glomerular filtration rate (eGFR) was 39 (30-58) mL/min/1.73 m2. All treated cases achieved a sustained virological response (SVR). Therapeutic drug monitoring of tacrolimus required slight adjustments of the tacrolimus dose. Regarding adverse events, a low-grade fever and mild renal dysfunction were observed in one case at 3 months. Despite withdrawing the treatment, this case still achieved SVR. The other cases showed no severe adverse events in liver or renal function. Conclusions: An IFN-free regimen of DCV/ASV therapy provided high tolerability and effectiveness in HCV-positive KT recipients, even under immunosuppressive conditions

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Liver: Disease & Transplantation
  • SubjectGastroenterology & Hepatology
  • SubjectSurgery
  • BylineArticles whose byline prints “Tomomi Kogiso”
  • BylineArticles whose byline prints “Etsuko Hashimoto”
  • BylineArticles whose byline prints “Kuniko Yamamoto”
  • BylineArticles whose byline prints “Yuichi Ikarashi”
  • BylineArticles whose byline prints “Kazuhisa Kodama”
  • BylineArticles whose byline prints “Makiko Taniai”
  • BylineArticles whose byline prints “Nobuyuki Torii”
  • BylineArticles whose byline prints “Kazunari Tanabe”